Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2016

The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. 

The Colloquia are organised by ESMO and supported by the industry and are unique collaborations offering early access to groundbreaking studies, making them the perfect complement to the scientific and educational programme of the Congress.

Friday, 7 October

ESMO Colloquium: Immuno-Oncology in Pole Position

ESMO Colloquium Immuno-Oncology in Pole Position square

Room: Brussels, 18:00-19:30
The ESMO Colloquium Immuno-Oncology in Pole Position is provided by ESMO and supported by Roche. 
View the ESMO colloquium details

Learning Objectives
  1. To understand the biology and role of the immune system in tumour development and proliferation
  2. To understand tumour escape mechanisms and the therapeutic options to manage such scenarios
  3. To understand the present status of biomarkers in guiding patient selection
  4. To understand the current role of immunotherapies in the context of the standard of care
  5. To understand the settings for the clinical application of immunotherapies and their practical application

Monday, 10 October

ESMO Colloquium Immune Checkpoint Inhibition and Chemotherapy in NSCLC and Breast Cancer: A Flamenco or a Tango?

ESMO Colloquium Immune Checkpoint Inhibition and Chemotherapy in NSCLC and Breast Cancer a Flamenco or a Tango square

Room: Madrid, 18:30-20:00
The ESMO Colloquium Immune checkpoint inhibition and chemotherapy in NSCLC and breast cancer is provided by ESMO and supported by Celgene.
View the ESMO colloquium details

Learning Objectives
  1. To learn about the biology of the immune cancer response, including immune cytotoxic and escape mechanisms
  2. To understand the evolving role of biomarkers for better patient selection and personalised treatment with immune checkpoint inhibitors
  3. To appreciate the differences in clinical outcomes according to tumour types
  4. To understand the factors involved in the modulation of activity and the development of resistance

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings